Combining fulvestrant (Faslodex™) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial

被引:19
作者
Dodwell, D. [1 ]
Coombes, G. [2 ]
Bliss, J. M. [2 ]
Kilburn, L. S. [2 ]
Johnston, S. [3 ]
机构
[1] St James Hosp, St James Inst Oncol, Leeds LS9 7TF, W Yorkshire, England
[2] Inst Canc Res, Clin Trial & Stat Unit ICR CTSU, Sutton SM2 5NG, Surrey, England
[3] Royal Marsden NHS Fdn Trust, Dept Med, London SW3 6JJ, England
关键词
D O I
10.1016/j.clon.2008.02.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:321 / 324
页数:4
相关论文
共 15 条
[1]   Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation [J].
Chan, CMW ;
Martin, LA ;
Johnston, SRD ;
Ali, S ;
Dowsett, M .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2002, 81 (4-5) :333-341
[2]   Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98 [J].
Coates, Alan S. ;
Keshaviah, Aparna ;
Thuerlimann, Beat ;
Mouridsen, Henning ;
Mauriac, Louis ;
Forbes, John F. ;
Paridaens, Robert ;
Castiglione-Gertsch, Monica ;
Gelber, Richard D. ;
Colleoni, Marco ;
Lang, Istvan ;
Del Mastro, Lucia ;
Smith, Ian ;
Chirgwin, Jacquie ;
Nogaret, Jean-Marie ;
Pienkowski, Tadeusz ;
Wardley, Andrew ;
Jakobsen, Erik H. ;
Price, Karen N. ;
Goldhirsch, Aron .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :486-492
[3]   Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J].
Coombes, R. C. ;
Kilburn, L. S. ;
Snowdon, C. F. ;
Paridaens, R. ;
Coleman, R. E. ;
Jones, S. E. ;
Jassem, J. ;
Van de Velde, C. J. H. ;
Delozier, T. ;
Alvarez, I. ;
Del Mastro, L. ;
Ortmann, O. ;
Diedrich, K. ;
Coates, A. S. ;
Bajetta, E. ;
Holmberg, S. B. ;
Dodwell, D. ;
Mickiewicz, E. ;
Andersen, J. ;
Lonning, P. E. ;
Cocconi, G. ;
Forbes, J. ;
Castiglione, M. ;
Stuart, N. ;
Stewart, A. ;
Fallowfield, L. J. ;
Bertelli, G. ;
Hall, E. ;
Bogle, R. G. ;
Carpentieri, M. ;
Colajori, E. ;
Subar, M. ;
Ireland, E. ;
Bliss, J. M. .
LANCET, 2007, 369 (9561) :559-570
[4]   Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors [J].
Dodwell, D. ;
Wardley, A. ;
Johnston, S. .
BREAST, 2006, 15 (05) :584-594
[5]   Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women [J].
Gibson, Lorna ;
Lawrence, David ;
Dawson, Claire ;
Bliss, Judith .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (04)
[6]  
GRADISHAR W, 2006, BREAST CANC RES T S1, V100
[7]   Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma - A prospectively planned combined survival analysis of two multicenter trials [J].
Howell, A ;
Pippen, J ;
Elledge, RM ;
Mauriac, L ;
Vergote, I ;
Jones, SE ;
Come, SE ;
Osborne, CK ;
Robertson, JFR .
CANCER, 2005, 104 (02) :236-239
[8]   Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].
Howell, A ;
Cuzick, J ;
Baum, M ;
Buzdar, A ;
Dowsett, M ;
Forbes, JF ;
Hoctin-Boes, G ;
Houghton, I ;
Locker, GY ;
Tobias, JS .
LANCET, 2005, 365 (9453) :60-62
[9]   Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive early-stage breast cancer: a meta-analysis [J].
Jonat, Walter ;
Gnant, Michael ;
Boccardo, Francesco ;
Kaufmann, Manfred ;
Rubagotti, Alessandro ;
Zuna, Ivan ;
Greenwood, Mike ;
Jakesz, Raimund .
LANCET ONCOLOGY, 2006, 7 (12) :991-996
[10]   Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial [J].
Lonning, PE ;
Bajetta, E ;
Murray, R ;
Tubiana-Hulin, M ;
Eisenberg, PD ;
Mickiewicz, E ;
Celio, L ;
Pitt, P ;
Mita, M ;
Aaronson, NK ;
Fowst, C ;
Arkhipov, A ;
di Salle, E ;
Polli, A ;
Massimini, G .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2234-2244